Table 1. Baseline characteristics of the entire cohort and divided into subgroups according to baseline LSM.
| Baseline characteristics |
Overall (n = 591) |
Baseline LSM <10kPa (n = 404) | Baseline LSM 10–16.9kPa (n = 100) | Baseline LSM 17-75kPa (n = 87) | p-value |
|---|---|---|---|---|---|
| n/median (IQR or %) |
n/median (IQR or %) |
n (IQR or %) | n (IQR or %) | ||
| Age | 46.1 (38.2–53.8) | 43.5 (36.1–51.6) | 49.8 (43.8–54) | 53.6 (46.8–56.9) | 0.0001 |
| Male sex | 379 (64.1) | 247 (61.1) | 66 (66) | 66 (75.9) | 0.031 |
| Western European | 508 (86) | 345(85.4) | 85 (85) | 78(89.7) | 0.558 |
| Genotype | 0.709 | ||||
| (n = 362/93/77a) | |||||
| 1 | 244 (45.8) | 165 (45.6) | 43 (46.2) | 36 (46.8) | |
| 2 | 45 (8.5) | 30 (8.3) | 8 (8.6) | 7 (9.1) | |
| 3 | 233 (43.6) | 160 (44.2) | 40 (43) | 32 (41.6) | |
| 4 | 10 (1.9) | 7 (1.9) | 1 (1.1) | 2 (2.6) | |
| 6 | 1 (0.2) | 0 | 1 (1.1) | 0 | |
| Cirrhosis at baseline | 108 (18.3) | 1 (0.25) | 20 (20) | 87 (100) | <0.005 |
| History of alcohol use | 324 (54.8) | 215 (53.2) | 55 (55) | 54(62.1) | 0.322 |
| History of IDU | 442 (74.8) | 305 (75.5) | 78 (78) | 59 (67.8) | 0.235 |
| HA in ng/mL | 36 (18–71) | 27 (15–44) | 62 (36–94) | 196 (92–416) | 0.0001 |
| ALT in U/L (342/75/76)a | 59 (38–105) | 55 (36–93) | 72 (45–135) | 75 (46–145) | 0.0006 |
| Platelet count in 10^9/L (336/75/75)a | 215 (168–262) | 232 (193–273) | 203 (158–266) | 122 (81–172) | 0.0001 |
| Albumin in g/L (342/76/76)a | 43 (40–45) | 43 (40–46) | 42 (40–44) | 39 (35–43) | 0.0001 |
|
Bilirubin in (343/76/76)a |
8 (6–12) | 8 (6–10) | 9 (7–13.5) | 12 (9–20.5) | 0.0001 |
|
INR (327/79/76)a |
1 (0.9–1.1) | 1 (0.9–1) | 1 (1–1.1) | 1.1 (1–1.3) | 0.0001 |
IDU; intravenous drugs, ALT; alanine aminotransferase.
aNumber of patients with baseline sample in baseline LSM 10kPa/10-16.9kPa/17-75kPagroups.